Track Categories

The track category is the heading under which your abstract will be reviewed and later published in the conference printed matters if accepted. During the submission process, you will be asked to select one track category for your abstract.

Biomarkers are the particles which demonstrate ordinary/anomalous process occurring in the body and may be the indication of a hidden condition or sickness. Different kinds of atoms can fill in as biomarkers, for example, DNA (genes), proteins or hormones since they all demonstrate the status of your wellbeing. 
 
Biomarkers participate in different procedures like diagnosis and prognosis, expectation and estimation of treatment reaction, and security assessment. The atomic biomarkers are solely being created and approved to be utilized as a part of medication improvement and are utilized to help endorsement of medication items.
 
  • Molecular biomarkers
  • Cancer biomarkers
  • Lipid biomarkers
  • Oncology biomarkers
  • Neurological biomarkers
  • Inflammatory & immunological biomarkers
  • Cardiovascular biomarkers
  • In-silico biomarkers
  • Pathological biomarkers
Personalized Medicine is known for its utilization of genomic data notwithstanding the family history, natural components and way of life to deal with the health. Exact expectations can be made about a man's weakness to building up an illness, the course of the ailment and to react to the treatment. Customized Medicine is another field of research and confirmation-based writing is required for incorporating into social healthcare delivery.
 
  • Personalised healthcare: translating scientific innovation into patient benefit
  • The future of targeted therapy and precision medicine
  • Updates on companion diagnostics development
  • The impact of patient self-monitoring in healthcare
  • Challenges of drug & diagnostics co-development
In the post-genomic time, it has turned out to be obvious that hereditary changes alone are not adequate to see most sickness forms including tumor. Genome sequencing has uncovered an unpredictable arrangement of hereditary changes in disease, for example, point transformations, chromosomal misfortunes, quality intensifications and telomere shortening that drive harmful development through specific signalling pathways.
 
Proteome-based methodologies are vital supplements to genomic information and give essential data of the objective driver particles and their post-translational changes. By applying quantitative mass spectrometry, this is an elective method to distinguish biomarkers for early diagnosis and personalized medicine.
 
  • Improving cancer patient care through translational science
  • Safety, efficacy and PK/PD biomarkers in drug development
  • Biomarkers for early identification of neurological disease
  • Biomarker development in metabolic and cardiovascular diseases
  • Predictive biomarkers for drug development
  • Translating biomarkers from discovery stages through to exploratory clinical testing
  • New advances in biomarker technologies and platform
Biomarker inquire about is a consistent procedure starting with revelation and then continues to approval process till the usage of biomarkers in the clinical setting. Hopeful biomarkers which are distinguished in disclosure organize should be approved over the quantity of tests. The test is to build up a quick and focused on investigation strategy that is equipped for dissecting whatever number recognized competitors as would be prudent in least hundred and possibly even a huge number of tests. Biomarker competitors distinguished amid revelation process are approved utilizing bigger examples which covers a wide area of patients. The check organize gives affirmation that a specific philosophy is reasonable to be utilized as a part of the validation stage.
 
  • Biomarkers in Patient Stratification and Translation
  • Microbiome Biomarkers for Parkinson’s disease
  • PDX – Patient Derived Xenograft models for Biomarkers
  • Companion and clinical diagnostics development as well as patient testing
  • Biomarker assay validation
The significant utilization of biomarkers in clinical examination is as clinical trials & monitoring. The whole range of infection from the soonest sign till the terminal stages might be reverberated through these biomarkers. Biomarker demonstrates the best connection between its reaction when it is contrasted with the wellbeing/biological impact. It gives assortment of human and creature materials chiefly through immuno-measures and quantitative PCR that can be diagnostically decided at any of the Biomarker Laboratory.
 
  • Overcoming challenges of clinical validation & translation
  • Advances in mass spectrometry, flow cytometry, digital pathology & imaging
  • Overcoming data handling and big data challenges
  • Implementing clinical biomarker in auto-immune diseases
  • Advancing clinical data and precisionmedicine
  • Surrogate endpoints: utilising biomarkers in clinical trials
In recent years, the utilization of high-throughput omics advances has prompted the fast revelation of numerous hopeful biomarkers. Notwithstanding, few of them have made the progress to the facility. In this survey, the guarantee of omics advances to add to the procedure of biomarker improvement is depicted. A diagram of the present state around there is given cases of genomics, proteomics, transcriptomics, metabolomics and micro biomics biomarkers in the field of oncology, alongside some proposed systems to quicken their approval and interpretation to enhance the care of patients with neoplasms. The inherent complexity underlying neoplasms joined with the prerequisite of growing all around planned biomarker disclosure forms in view of omics advancements introduce a test for the compelling improvement of biomarkers that might be helpful in managing treatments, tending to illness hazards, and anticipating clinical results.
 
  • Transforming clinical development through biomarker driven clinical trials design
  • The use of proteomic and metabolomic biomarkers in the clinic
  • NGS & Genomic Marker Development
  • Translating CTCs and ctDNA for Clinical Use
  • The importance of liquid biopsies for precision medicine in cancer
  • microRNA, cfDNA as Emerging Biomarkers

 

There is developing logical enthusiasm for the examination of metabolomics and quantities of studies have concentrated on the use of non-intrusive biomarkers in the determination.
 
  • Circulating free tumour DNA
  • Circulating micro RNA
  • Circulating Tumour Cells
  • Fluid & Blood Biopsy Biomarkers
  • Non-Invasive Prenatal Testing
 
Biomarkers of illness assume a critical part in prescription and have started to accept a more prominent part in medicate disclosure and advancement. The test for biomarkers is to permit prior, more powerful medication wellbeing and adequacy estimations. Their part in tranquilize advancement will keep on growing for years to come. For biomarkers to accept their legitimate part, more prominent comprehension of the instrument of ailment movement and helpful intercession is required. What's more, more noteworthy comprehension of the prerequisites for biomarker choice and approval, biomarker examine strategy approval and application, and clinical endpoint approval and application is required. Biomarkers should be considered while the remedial target is yet being distinguished and the idea is being defined.
 
  • Precision Medicine in Auto-Immune Diseases
  • Translation medicine in CNS
  • Medicine Development in Oncology and Infectious Diseases
  • Drug discovery innovation and strategies
  • Phenotypic and genomic drug discovery
  • Computational chemistry and informatics for drug discovery
Screening for early invasive disease has the potential to reduce mortality from cancer. Because of their ease of measurement, several biomarkers have been evaluated or are currently undergoing evaluation as screening tests for early cancer. These include the use of biomarkers in screening for cancer in high-risk subjects. Although biomarkers have many attractive features as cancer screening tests, lack of sensitivity and specificity, when combined with the low prevalence of specific cancer types in asymptomatic subjects, limit their application for the early detection of cancer.
 
  • Breast cancer screening 
  • Cervical cancer screening 
  • Bowel cancer screening 
  • Prostate cancer screening 
  • Lung cancer screening 
  • Pancreatic cancer screening
There are numerous types of cancerbiomarkers, and they each work contrastingly inside the body and respond diversely to medicines. In general, cancer biomarkers are grouped by their distinctive capacities. Tumor biomarkers can incorporate, proteins, gene transformations & changes, gene adjustments, extra duplicates of genes, missing genes and other molecules.
 
  • Lung cancer biomarkers 
  • Prostate cancer biomarkers 
  • Breast cancer biomarkers
  • Biomarkers for Alzheimer
  • Advanced biomarkers for cancer 
Biomarkers give a dynamic and ground-breaking way to deal with understanding the range of neurological sickness with applications in observational and explanatory the study of disease transmission, randomized clinical trials, screening and diagnosis and prognosis. Characterized as adjustments in the constituents of tissues or body liquids, these markers offer the methods for homogeneous arrangement of a malady and hazard factors, and the can expand our base data about the fundamental pathogenesis of ailment. Biomarkers can likewise mirror the whole range of malady from the soonest signs to the terminal stages.
 
  • Uses of biomarkers in cancer medicine 
  • Uses of Molecular or Biochemical Biomarkers
  • Uses of Physiologic biomarkers
  • Uses of Anatomic biomarkers
Circulating biomarkers incorporates markers as straightforward as glucose or cholesterol and also protein biomarkers, for example, C-responsive protein (CRP), circling without cell DNA (cfDNA), or flowing RNA. In more up to date cases, it likewise incorporates qualities, for example, BCRA1, KRAS, and others. As of late, the field has extended to incorporate coursing tumor cells (CTCs) and exosomes or extracellular vesicles (EVs). Circling biomarker examine thinks about spotlight on a few analyte classes/gatherings. As of late, there has been expanding enthusiasm for a couple of these classes.
 
  • Exosomes
  • Microvesicles
  • Circulating-Free DNA (cfDNA)
  • Circulating RNA
  • Circulating Tumor Cells (CTCs)
Biomarkers have a few uses in pharmaceutical Research and Development. With the ongoing presentation of superior instrumentation, protein and gene clusters and bioinformatics, clinical choices like Drug improvement and picking sort of treatment can be made productively. Be that as it may, there is an absence of legitimate biomarkers to expand the medication advancement from pre-clinical through all levels of clinical investigations. Biomarker in Drug Discovery can likewise prompt improvement of Personalized Medicines. 
 
Biomarkers empower quantitation of the degree to which new medications achieve planned targets, adjust proposed pathophysiological instruments and accomplish clinical results. The Biomarkers challenge is to distinguish exceptional sub-atomic marks in complex organic blends that can be unambiguously associated to natural occasions keeping in mind the end goal to affirm novel medication targets and anticipate sedate reaction. Biomarkers can measure medicate help with essential evasion or sickness alteration examines or to isolate persistent populaces in deficiently served locales, for example, neurodegeneration and cancer. Clinically important biomarkers are required to tell administrative and medicinal basic leadership to new medications and their signs keeping in mind the end goal to pass on new pharmaceuticals to the correct patients speedier than they are today.
 
  • Cardiovascular
  • Rheumatology
  • Respiratory
  • COPD
  • Rare Diseases
  • Infectious Diseases
  • Inherited Diseases
The advancements in the field of biomarkershas been a brilliant development. Different new advancements and explores been occurring for more extension of the innovation. Imaging to screening, all needs more extensive development too.
 
  • Assay Development
  • Imaging
  • Bioinformatics
  • Trial Design
  • Data Management
  • Imaging Technologies
The presence of contaminants in EVs segregated by the customary strategies recorded meddles with mass spectrometry and is a noteworthy hindrance in exosome molecular profiling and biomarkercontemplates.
 
  • Exosomes and Micro vesicles in Biological Fluids
  • Liquid Biopsies for Inherited Diseases
  • Fluid & Blood Biopsy Biomarkers
  • Examples of Translation into the Clinic
A biomarker is a characterized trademark that is utilized as a marker of typical organic procedures, pathogenic procedures or reactions to a restorative intercession. Biomarkers are perceived as basic tools for the development of therapeutics, permitting enhanced and better educated clinical trial outline through pointers of target commitment and those that empower tolerant stratification. Moreover, biomarkers can encourage the assessment of helpful mediation on malady movement or repeat. Even though biomarker disclosure is an exceptionally dynamic research zone, few biomarkers have been adequately approved for use in clinical practice or clinical trials.
 
  • Methodologies and Applications
  • Isolation
  • Capture
  • Biomarker Cargo Analysis
There are a several kinds of biomarkers, which satisfy distinctive parts over the continuum of care. By dissecting biomarkers, symptomatic tests might have the capacity to give data about early tumor improvement to identify cancer at an early, more treatable stage. These biomarkers can be useful in curing patients in different various settings.
 
  • Risk Assessment 
  • Screening/Detection
  • Diagnosis
  • Prognosis
  • Prediction
  • Monitoring
Biomarkers are proposed to replace surrogate endpoints in clinical preliminaries process. Surrogate markers are utilized to direct the clinical trial and assemble a few endpoints which is illogical when the essential endpoint is undesired, or the occasion number is little. Biomarkers help in the diagnostics and clinical advancement forms. Biomarkers contextual analysis assumes a vital part in finding new medications for the patients who require new medications and to be utilized broadly in different clinical practices.
 
  • MicroRNA’s
  • CTCs
  • Circulating free DNA
  • Exosomes
  • Biomarker to Diagnostic
Biomarker classification depends on its context of utilization, which thoroughly characterizes the degree to which the biomarker must be "validated." as far as necessities for approval, the "blessed vessel" of biomarker application is one that can fill in as a surrogate endpoint in a clinical trial. A surrogate endpoint is a research facility (or physical) estimation that is utilized as a part of a clinical trial as a substitute for a clinical endpoint (e.g., survival or practical endpoint). Subsequently, a surrogate endpoint should precisely anticipate the impact of therapeutic intervention.
 
  • Collaborating with other disciplines
  • Non-invasive & least-invasive Biomarkers
  • The Latest Oncology Diagnostics
  • Informatics in Personalized Medicine
  • Novel approaches to drug design
  • Application of Genetics/Genomics in the Clinic
CRO offers help to the pharma businesses as research administrations outsourced on contract premise. In the lead of clinical preliminaries, a support is an individual/ foundation/ organization/ association that assumes liability to start, oversee or back clinical preliminary, however it doesn't direct the examination. The support is obligation is for actualizing and keeping up QA and QC frameworks with composed SOPs to guarantee that preliminaries are directed, and information is produced, archived, and announced in consistence with the convention, GCP, and the pertinent administrative prerequisite.
 
  • Business development tactics
  • Strategies to attract sponsors
  • Clinical Trials for Small Sponsors
  • Evolving Strategic Partnerships
  • Patient-pharma relationship CR
The clinical trials are the logical investigations of impacts, dangers, viability and advantages of new and notwithstanding existing drugs. Trials should be completed before an item achieves the healing centre or nearby drug store. They are attempted at different stages, or say 'stages', and incorporate trials on solid people; patients with an ailment; and likewise thinks about directed after the dispatch of the new item to screen wellbeing and symptoms amid huge scale utilize. Clinical preliminaries are directed by pharmaceutical organizations or Contract Research Organizations for their sake. There are different parts and duties in these periods of Clinical Trials.
 
  • Clinical CROs 
  • BA/BE Centers
  • SMOs 
  • Data Management 
  • IT Companies in Healthcare/Clinical Domains
  • Central Laboratories
  • Packaging & Labeling
  • Investigator & Site Staffs
Pharmacovigilance and Risk Management was intended for giving a comprehension of hazard administration in human services activities and applications. Pharmacovigilance is characterized as the science and the exercises identifying with the recognition, evaluation, understanding and even counteractive action of unfriendly impacts or some other medication related issue. The points of PV is to improve quiet care and patient wellbeing in connection to use of drugs.
 
  • Ecopharmacovigilance
  • PV: Current Regulation & Challenges
  • Pharmacovigilance and Risk Management
  • Pharmacovigilance Significance & Scope
  • PV Consulting’s and Business opportunity
  • Adverse Drug Reactions
In-house treatment of clinical preliminaries can now and again be a managerial and functional weight. By halfway outsourcing clinical preliminary dispersion, pharmaceutical research associations will frequently have the capacity to free up interior assets and in the meantime improve security and nature of the conveyance of their preliminary drug. It can help in various stages like:
  • Forecasting 
  • Stock Management 
  • IRT Med Management 
  • Temperature Services 
  • Mass Drug Management 
  • Examiner Initiated Trials and Specialized Clinical Programs 
  • Drug store Services